Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma.
Vascular endothelial growth factor (VEGF) plays an important role in angiogenesis and progression of cancer and its expression was associated with gene polymorphisms. Since the impact of polymorphisms of the VEGF on non-Hodgkin lymphoma prognosis has not been fully elucidated, we investigated 149 diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at the National Cancer Center, Korea. Five polymorphisms were analyzed with clinical characteristics as well as international prognostic index (IPI). Hazard ratios (HRs) were determined for overall survival (OS) and progression-free survival (PFS). The rs1570360 polymorphism exhibited a genotype frequency of GG (76%), GA (20%), and AA (4%), and it was significantly associated with poor prognosis in DCBCL patients treated with R-CHOP with HR of 2.44 [95% confidence interval (CI), 1.29-4.63; p = .0064]. These findings suggest VEGF polymorphisms might be significant prognostic indicators for DLBCL treated by R-CHOP.
a Center for Breast Cancer , Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center , Goyang , Republic of Korea.|b College of Veterinary Medicine , Konkuk University, Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center , Goyang , Republic of Korea.
Kyong-Ah
KA
Yoon
c Department of System Cancer Science, Graduate School of Cancer Science and Policy , Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center , Goyang , Republic of Korea.
Min Kyeong
MK
Kim
d Hematology-Oncology Clinic, Center for Specific Organs Cancer , Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center , Goyang , Republic of Korea.
Hyeon-Seok
HS
Eom
d Hematology-Oncology Clinic, Center for Specific Organs Cancer , Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center , Goyang , Republic of Korea.
Hyewon
H
Lee
e Department of Pathology , Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center , Goyang , Republic of Korea.
Weon Seo
WS
Park
f Department of Laboratory Medicine , Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center , Goyang , Republic of Korea.
Ji Yeon
JY
Sohn
g Department of Laboratory Medicine , Seoul National University Hospital, Seoul National University College of Medicine , Seoul , Republic of Korea.
Man Jin
MJ
Kim
c Department of System Cancer Science, Graduate School of Cancer Science and Policy , Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center , Goyang , Republic of Korea.|d Hematology-Oncology Clinic, Center for Specific Organs Cancer , Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center , Goyang , Republic of Korea.|f Department of Laboratory Medicine , Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center , Goyang , Republic of Korea.
Sun-Young
SY
Kong
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D000069283:Rituximab / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*; D014750:Vincristine / Q000008:administration & dosage
D042461:Vascular Endothelial Growth Factor A; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
Diffuse large B-cell lymphoma; polymorphism; prognostic marker; vascular endothelial growth factor